These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Evaluation of 68Ga-PSMA PET/CT with volumetric parameters for staging of prostate cancer patients.
    Author: Aksu A, Karahan Şen NP, Tuna EB, Aslan G, Çapa Kaya G.
    Journal: Nucl Med Commun; 2021 May 01; 42(5):503-509. PubMed ID: 33560717.
    Abstract:
    BACKGROUND: The aim of this study was to investigate the relationship between volumetric data obtained from staging 68Ga-prostate-specific membrane antigen (PSMA) PET computerized tomography (CT) images with prostate-specific antigen (PSA), risk groups, Gleason Grade (GG) groups and presence of metastasis. METHODS: We performed a retrospective analysis of 68Ga-PSMA PET-CT images from 88 patients undergoing initial staging of prostate adenocarcinoma between January 2015 and September 2018. Images were evaluated in LIFEx software; PSMA involvement above the background activity in prostate gland, lymph node and other distant metastases was plotted with 40% SUVmax threshold, SUVmax, PSMA tumor volume (PSMA-TV) and total lesion PSMA (TL-PSMA) values were obtained. RESULTS: In all patients, there was a moderate correlation between PSA and PSMA-tumor volume whole-body (PSMA-TVwb) (P < 0.001, r = 0.580) and a high correlation between total lesion-PSMAwb (TL-PSMAwb) (P < 0.001, r = 0.636). Prostate PSMA-TV (PSMA-TVp) and TL-PSMA (PSMA-TVp) values were different in local and locally advanced/metastatic patients (P = 0.020 and 0.006, respectively). PSMA-TVp and TL-PSMAp values were significantly different in low-moderate and high-risk patients (P = 0.003 and <0.001, respectively), and in patients with and without metastasis (P = 0.008 and <0.001, respectively). PSMA-TVp, PSMA-TVwb, TL-PSMAp and TL-PSMAwb values were significantly different in patients with GG ≤3 and >3 (P = 0.030, 0.002, <0.001 and <0.001, respectively). CONCLUSION: Pretreatment 68Ga-PSMA PET/CT volumetric parameters provides unique data to use in the clinical decision-making process of patients with adenocarcinoma of the prostate.
    [Abstract] [Full Text] [Related] [New Search]